AustraliaBreaking News

Australian RegTech company, Kinatico (ASX:KYP), reported continued strong growth in its SaaS business, posting unaudited flash results for the first half of the 2026 financial year.

Job vacancies in Australia fell slightly by 0.2% in the three months to November 2025, according to new quarterly figures released by the Australian Bureau of Statistics.

Neuren Pharmaceuticals (ASX:NEU) highlighted key updates from its partner Acadia Pharmaceuticals' (NASXDAQ:ACAD) presentation at the 44th annual J.P. Morgan Healthcare Conference.

Australian medicinal cannabis leaders Little Green Pharma (ASX:LGP) and Cannatrek have entered into a binding scheme implementation deed, under which LGP will acquire 100% of Cannatrek’s issued capital via a scheme of arrangement.

Power Minerals (ASX:PNN) will terminate its joint venture with Navigate Energy Technology Limited over the Rincon Lithium Project.

HighCom (ASX:HCL) has provided an update on its first-half trading for FY26, with revenue expected between $10.5 million and $11 million and an EBITDA loss of $5 million to $5.8 million.

Prospect Resources (ASX:PSC) has confirmed significant by-product gold mineralisation at its Nyungu Central deposit, part of the Mumbezhi Copper Project in north-west Zambia.

Argent BioPharma (ASX:RGT) has entered a binding agreement with AusCann Group (ASX:ACN) to acquire AusCann's 48% equity interest in CannPal for $2 million in Argent shares at 10 cents per share.

Austral Resources Australia (ASX:AR1) has signed a non-binding memorandum of understanding with Transition Resources to assess the potential toll treatment of Transition’s ore at Austral’s Rocklands processing facility in Northwest Queensland.

Record electricity prices in Western Australia's wholesale energy market in 2025 are intensifying calls for new generation projects, with Frontier Energy (ASX:FHE) accelerating studies for its Waroona Renewable Energy Project.

BlueScope Steel (ASX:BSL) will return $438 million in surplus cash to shareholders through an unfranked special dividend of $1 per share.

AVITA Medical (ASX:AVH) reported preliminary unaudited results for the fourth quarter and full year of fiscal 2025, highlighting year-on-year revenue growth, a new US$60 million debt facility, and a positive revenue outlook for 2026.